Clinical trials in asthma
A great deal of medical research depends on the recruitment of patients into clinical trials. Little attention has been paid, however, to patients' attitudes to such research and their reasons for giving their informed consent. Cassileth et all recently investigated these attitudes in patients with cancer and heart disease and in 107 members of the general public. The three groups gave similar answers, over 70% believing that patients should be willing to take part in research. When asked what would be their main reason for their personal participation 52% said that it would be to help them to get the best medical care. This expectation of some medical benefit outside the trial re-emphasises how careful investigators must be adequately to protect their patients in the design of and recruitment for such studies. Ethical committees and researchers should remember the Declaration of Helsinki, which states: "Clinical research cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject."2 The much vaunted double blind randomised crossover trial of treatments relies on patients entering each limb of the trial with their disease in the same baseline state. Trials of conditions which show spontaneous fluctuations may, therefore, be frustrating. In asthma this very variability is used as a defining characteristic of the disease,3 while the -esponses to bronchodilating and bronchoconstricting stimuli are closely related to the initial airway calibre.4 All trials in asthma should have adequate control for the placebo responses that often occur, and investigators should also be "blinded," since any suggestion of the expected effects of a treatment may itself modify the changes produced. The sudden fluctuations in airflow obstruction characteristic of asthma mean that acute exacerbations will occur whether or not patients are included in clinical trials at the time. In these circumstances patients may be reluctant to upset research studies by adjusting their treatment, so they must be told exactly what they should do. They should also be able to get in touch with one of the trial organisers at once for further advice.
The alternatives to the use of asthmatic patients in clinical trials are animal studies and the use of normal people. Many animal systems have been used, but none provides a really satisfactory model of human asthma. Normal people are used less often than they might be to look for bronchodilator responses. Changes in values such as FEV1 are small, but useful information can be obtained by measuring airways resistance in the body plethysmograph or by observing the effects of bronchodilators on induced bronchoconstriction. 22 In normal individuals there is no danger of precipitating severe bronchoconstriction if the dose of the provoking agent is increased in a steady stepwise fashion, and the problems ofvarying baselines and other interacting treatments are also avoided. Some research workers have been fortunate enough to have their own personal hyperreactive airways to use for preliminary studies. 23 Although such normal people might be used more often, the introduction of new treatments and the development of existing ones will continue to depend on assessment of responses in asthmatic patients. We must ensure that the information sought by the trials is important enough to justify any inconvenience and risk to the patient. The 
